age ≥ 3 years

diagnosis of ALD, as established by elevation of very long chain fatty acid levels or gene mutation

evidence of active cerebral disease as determined by the presence of gadolinium enhancement

ALD MRI (Loes) score ≥ 1

Patients who have not received prior gene therapy or transplant

Life expectancy of \> 6 months as determined by the enrolling researcher

Have adequate organ function confirmed by laboratory values obtained within 28 days prior to enrollment

MT2022-01: MSCs for ALD